All In Biotech

Drug Trial Radar · NCT07511010

Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets

A Phase I Clinical Study to Assess the Food Effect and Multiple Dose Pharmacokinetic of Chiglitazar/Metformin Extended-Release Fixed Dose Combination Tablets

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

Sep 10, 2026

Primary completion

Oct 22, 2026

Study completion Oct 25, 2026

Sponsor

Lead sponsor
Chipscreen Biosciences, Ltd.Industry
Sponsor type
Industry
First posted
Apr 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This trial includes two parts: a food effect (FE) study and a multiple-dose pharmacokinetic (PK) study. The FE study is a randomized, open-label, two-period, two-sequence crossover study designed to evaluate the effect of a high-fat meal on the PK of a single oral dose of Chiglitazar/Metformin extended-release tablets in healthy adult Chinese participants. The multiple-dose PK study is an open-label study designed to evaluate the PK characteristics of Chiglitazar/Metformin extended-release tablets in healthy adult Chinese participants following multiple oral doses.

Conditions

  • T2DM (Type 2 Diabetes Mellitus)

Interventions

  • Chiglitazar/Metformin extended-release tablets under fasting conditionsDrug

    a single dose of Chiglitazar/Metformin extended-release tablets under fasting conditions

  • Chiglitazar/Metformin extended-release tablets after a high-fat mealDrug

    a single dose of Chiglitazar/Metformin extended-release tablets after a high-fat meal

  • multiple-dose of Chiglitazar/Metformin extended-release tabletsDrug

    a single dose on Day 1, once-daily consecutive doses from Day 4 to Day 10

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. FE Study: Maximum plasma concentration (Cmax)Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours
  2. FE Study: Area Under the Plasma Concentration-Time Curve (AUC)Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours
  3. FE Study: Time to Maximum Plasma Concentration(Tmax)Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours
  4. FE Study: Elimination Half-life (t1/2)Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours
  5. FE Study: Apparent Total Clearance (CL/F)Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours
  6. FE Study: Apparent Volume of Distribution during the terminal phase (Vz/F)Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours
  7. Multiple-dose PK study: Maximum plasma concentration (Cmax)Time frame: predose to 72 hours after the last dose (7 consecutive days of dosing)
  8. Multiple-dose PK Study: Area Under the Plasma Concentration-Time Curve (AUC)Time frame: predose to 72 hours after the last dose (7 consecutive days of dosing)
  9. Multiple-dose PK Study: Time to Maximum Plasma Concentration(Tmax)Time frame: predose to 72 hours after the last dose (7 consecutive days of dosing)
  10. Multiple-dose PK Study: steady-state peak concentration (Cmax,ss)Time frame: predose to 72 hours after the last dose (7 consecutive days of dosing)
  11. Multiple-dose PK Study: steady-state time to peak concentration (Tmax,ss)Time frame: predose to 72 hours after the last dose (7 consecutive days of dosing)
  12. Multiple-dose PK Study: under the plasma concentration-time curve at steady state (AUCss)Time frame: predose to 72 hours after the last dose (7 consecutive days of dosing)
  13. Multiple-dose PK Study: trough concentration (Ctrough)Time frame: predose to 72 hours after the last dose (7 consecutive days of dosing)
  14. Multiple-dose PK Study: accumulation ratio (Rac)Time frame: predose to 72 hours after the last dose (7 consecutive days of dosing)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Ditan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.